The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued recommendations supporting approval for several new drugs and vaccines, including filings from Jiangsu Hansoh Pharmaceutical and Cytokinetics. The December meeting recommended five new authorizations, highlighting continued regulatory momentum in oncology and rare diseases. CHMP opinions are a key step toward EU approval and often presage national market access decisions. Sponsors will now complete formal European Commission procedures and national rollouts pending final authorization.